Curis, Inc.
$0.62
▲
3.17%
2026-04-21 06:13:01
www.curis.com
NCM: CRIS
Explore Curis, Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$24.33 M
Current Price
$0.62
52W High / Low
$3.13 / $0.49
Stock P/E
—
Book Value
$0.42
Dividend Yield
—
ROCE
-558.61%
ROE
2829.1%
Face Value
—
EPS
$-0.58
Exp Qtr EPS
—
Sector
Healthcare
Industry
Biotechnology
Employees
20
Beta
3.14
Debt / Equity
29.62
Current Ratio
0.49
Quick Ratio
0.49
Forward P/E
-0.52
Price / Sales
2.12
Enterprise Value
$16.54 M
EV / EBITDA
-0.51
EV / Revenue
1.75
Rating
Strong Buy
Target Price
$14
EPS Forecast (FY)
—
Pros
- Healthy return on equity.
- Balance sheet leverage appears manageable.
- Valuation is not stretched on P/E basis.
Cons
- Capital efficiency is modest.
- Current ratio suggests tighter short-term liquidity.
- Operating margin is thin.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | Agios Pharmaceuticals, Inc. | $27.07 | — | $1.54 B | — | -38.86% | -30.2% | $46 / $22.24 | $20.41 |
| 2. | Nkarta, Inc. | $3.49 | — | $247.38 M | — | -31.94% | -28.9% | $3.48 / $1.63 | $4.39 |
| 3. | Theriva Biologics, Inc. | $0.41 | — | $18.89 M | — | -85.21% | -1.38% | $1.5 / $0.16 | $0.43 |
| 4. | Cognition Therapeutics, Inc. | $1.12 | — | $106.33 M | — | -70.77% | -88.59% | $3.83 / $0.22 | $0.39 |
| 5. | NovaBay Pharmaceuticals Inc | $1.4 | — | $51.92 M | 0% | -96.1% | 190.01% | $99.75 / $1.11 | $-0.92 |
| 6. | Arcellx, Inc. | $115 | — | $6.73 B | — | -50.64% | -53.42% | $115.13 / $47.86 | $6.95 |
| 7. | Cartesian Therapeutics, Inc. | $6.94 | — | $183.97 M | — | -30.8% | 195.88% | $15.57 / $5.6 | $-4.85 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|
| Sales | 1.14 M | 3.18 M | 2.75 M | 2.38 M | 3.35 M | — |
| Operating Profit | -7.57 M | -6.92 M | -8.25 M | -10.16 M | -8.99 M | — |
| Net Profit | 19.36 M | -7.73 M | -8.59 M | -10.62 M | -9.62 M | — |
| EPS in Rs | 0.48 | -0.19 | -0.21 | -0.27 | -0.24 | — |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 9.44 M | 10.91 M | 10.02 M | 10.16 M |
| Operating Profit | -32.9 M | -44.54 M | -48.33 M | -53.02 M |
| Net Profit | -7.58 M | -43.39 M | -47.41 M | -56.67 M |
| EPS in Rs | -0.19 | -1.09 | -1.19 | -1.42 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 19.97 M | 41.27 M | 77.28 M | 108.85 M |
| Total Liabilities | 14.5 M | 47.26 M | 57.61 M | 62.3 M |
| Equity | 5.46 M | -6 M | 19.67 M | 46.55 M |
| Current Assets | 6.92 M | 26.39 M | 60.91 M | 92.12 M |
| Current Liabilities | 14.08 M | 19.03 M | 22.02 M | 10.01 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | -27.2 M | -39.56 M | -38.43 M | -54.34 M |
| Investing CF | 2.5 M | 29.44 M | 37.79 M | 33.02 M |
| Financing CF | 9.77 M | 3.44 M | 7.58 M | 0.87 M |
| Free CF | -27.2 M | -39.56 M | -38.43 M | -54.75 M |
| Capex | — | — | — | -0.42 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Revenue Growth % | 8.83% | -1.37% | — | — |
| Earnings Growth % | 8.49% | 16.34% | — | — |
| Profit Margin % | -397.77% | -473.04% | -557.69% | — |
| Operating Margin % | -408.34% | -482.21% | -521.75% | — |
| Gross Margin % | 99.1% | 97.88% | 97.47% | — |
| EBITDA Margin % | -390.27% | -450.35% | -508.44% | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
No stock split history available.